FULC Q3 2020 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FULCFulcrum Therapeutics, Inc.

$411M

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M

Gross Profit

-$14M-746.3% margin

Operating Income

-$19M-1033.8% margin

Net Income

-$19M-1026.1% margin

EPS (Diluted)

$-0.70

QoQ Revenue Growth

-7.6%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$142M

Total Liabilities

$37M

Stockholders' Equity

$105M

Cash & Equivalents

$85M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$0	—
Gross Profit	-$14M	-$13M	-2.2%
Operating Income	-$19M	-$17M	-12.3%
Net Income	-$19M	-$17M	-14.6%